APICES speaking in Clinical Operations in Oncology Clinical Trials in Europe, Zurich. How to succeed in your oncology clinical trials from regional-medium CRO’S point of view. A pleasure to share our view with you. APICES in CTO Europe Clinical Operations in Oncology Trials Europe 2022
Today starts Clinical Operations in Oncology Trials Europe. APICES is speaking about why medium/regional CROs are the best choice in Oncology trials. Clinical Operations in Oncology Trials Europe 2022
APICES is actively participating in the upcoming CLINICAL OPERATIONS IN ONCOLOGY TRIALS EUROPE 2022 congress in Zurich. In the following link you can access the agenda. Clinical Operations in Oncology Trials Europe 2022 On November 23rd, Ana Moreno, Director Global Clinical Operations at APICES, will give us her opinion regarding how to succeed in your…
It is a pleasure for APICES to cooperate with this multidisciplinary congress in head and neck cancer where clinical research is a must. Congrats to organisers, speakers, sponsors and attendees. Inicio – I Congreso de la FETTCC (fundacionttcc.com)
This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial”. published in…
This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy” published in Supportive Care in…
We are very happy to inform you that APICES has applied to the French Ministry of Research as an organisation carrying out research and development (R&D) and this application has been approved for the years 2022, 2023 and 2024. This approval recognises APICES’s ability to carry out R&D work on behalf of clients. APICES will…
Once more time we are privileged to share the acknowledgment that APICES has received in the recent publication titled: “Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder”. This is an extra motivation for the whole APICES team. These achievements would not be possible without the involvement of every…
Once more time we are privileged to share the acknowledgment that APICES has received in the recent publication titled: “High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial”. This is an extra motivation for the whole APICES team. These achievements would not be…
We are privileged to share the acknowledgment that APICES has received in the recent publication titled: “Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy”, a study in which APICES has participated in study design, setup,…